[go: up one dir, main page]

PE20010574A1 - Derivados de indol como ligandos del receptor 5-ht2 - Google Patents

Derivados de indol como ligandos del receptor 5-ht2

Info

Publication number
PE20010574A1
PE20010574A1 PE2000000807A PE0008072000A PE20010574A1 PE 20010574 A1 PE20010574 A1 PE 20010574A1 PE 2000000807 A PE2000000807 A PE 2000000807A PE 0008072000 A PE0008072000 A PE 0008072000A PE 20010574 A1 PE20010574 A1 PE 20010574A1
Authority
PE
Peru
Prior art keywords
alkyl
indeol
derivatives
tetrahydrocyclopenta
indol
Prior art date
Application number
PE2000000807A
Other languages
English (en)
Inventor
Jonathan Mark Bentley
Jonathan Richard Anthony Roffey
Richard John Hamlyn
Nathaniel Julius Monck
Howard Langham Mansell
Ian Anthony Cliffe
David Reginald Adams
James Edward Paul Davidson
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Publication of PE20010574A1 publication Critical patent/PE20010574A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A INDOLES CONDENSADOS EN LAS POSICIONES 2,3 A UN ANILLO INSATURADO DE FORMULA I, DONDE; R1 Y R2 SON H, ALQUILO; R3 ES ALQUILO; R4, R6 Y R7 SON H, HALOGENO, OH, ALQUILO, ARILO, ENTRE OTROS; R5 ES H, HALOGENO, OH, ALQUILO, ARILO, AMINO, ENTRE OTROS; A ES UN HETEROCICLO DE 5-6 MIEMBROS, CARBOCICLO DE 5-6 MIEMBROS; SI A ES UN ANILLO CARBOCICLICO DE 6 MIEMBROS; ENTONCES AL MENOS UNO DE R4 Y R7 NO ES H. SON COMPUESTOS PREFERIDOS (S)-1-(7,8-DIFLUORO-1,2,3,4-TETRAHIDROCICLOPENTA[b]INDOL-4-IL)-2-PROPILAMINA, (S)-1-(7-FLUORO-1,2,3,4-TETRAHIDROCICLOPENTA[b]INDOL-4-IL)-2-PROPILAMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN AGONISTA O ANTAGONISTA DEL RECEPTOR 5-HT Y PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS DEPRESION, PSICOSIS, ESQUIZOFRENIA, MIGRANA, DIABETES INSIPIDA, APNEA, MOTILIDAD GASTROINTESTINAL, OBESIDAD
PE2000000807A 1999-08-11 2000-08-09 Derivados de indol como ligandos del receptor 5-ht2 PE20010574A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918962.3A GB9918962D0 (en) 1999-08-11 1999-08-11 Chemical compounds xxii

Publications (1)

Publication Number Publication Date
PE20010574A1 true PE20010574A1 (es) 2001-05-21

Family

ID=10858982

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000807A PE20010574A1 (es) 1999-08-11 2000-08-09 Derivados de indol como ligandos del receptor 5-ht2

Country Status (21)

Country Link
US (1) US6706750B1 (es)
EP (1) EP1202965B1 (es)
JP (1) JP2003507367A (es)
KR (1) KR100740172B1 (es)
CN (1) CN1187330C (es)
AR (1) AR037222A1 (es)
AT (1) ATE279392T1 (es)
AU (1) AU773337B2 (es)
BR (1) BR0013307A (es)
CA (1) CA2377646A1 (es)
DE (1) DE60014918T2 (es)
DK (1) DK1202965T3 (es)
ES (1) ES2228588T3 (es)
GB (1) GB9918962D0 (es)
MX (1) MXPA01013235A (es)
PE (1) PE20010574A1 (es)
PT (1) PT1202965E (es)
TR (1) TR200200352T2 (es)
UY (1) UY26291A1 (es)
WO (1) WO2001012603A1 (es)
ZA (1) ZA200110217B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
MXPA03003246A (es) * 2000-10-16 2003-06-06 Hoffmann La Roche Derivados de indolina y su uso como ligandos del receptor 5-ht2.
ATE406371T1 (de) * 2000-11-02 2008-09-15 Us Gov Health & Human Serv Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
ATE433962T1 (de) 2000-11-20 2009-07-15 Biovitrum Ab Publ Piperazinylpyrazinverbindungen als antagonisten des serotonin-5-ht2-rezeptors
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
PL206962B1 (pl) * 2001-12-19 2010-10-29 Bristol Myers Squibb Co Związek heterocykliczny o budowie skondensowanej
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
AU2003243089B2 (en) 2002-06-19 2010-01-07 Biovitrum Ab (Publ) Novel compounds, their use and preparation
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
BRPI0508814B8 (pt) 2004-03-15 2021-05-25 Ptc Therapeutics Inc derivados de carbolina, bem como uso dos mesmos e composição farmacêutica
US8076353B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
JP2007529533A (ja) * 2004-03-15 2007-10-25 ピーティーシー セラピューティクス，インコーポレーテッド 血管新生の抑制に有用なテトラサイクリックカルボリン誘導体
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006065480A2 (en) * 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
CN101119717A (zh) * 2004-11-23 2008-02-06 Ptc医疗公司 用作抑制vegf产生的活性剂的取代酚
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
WO2023114238A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Aryloxy psychoplastogens and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2541211A (en) 1948-10-15 1951-02-13 Searle & Co Tertiary-aminoalkyl-tetrahydrocarbazoles
US2687414A (en) * 1948-11-26 1954-08-24 Searle & Co Method for producing aromatic aminoalkyl amines
DE930988C (de) 1953-01-01 1955-07-28 Bayer Ag Verfahren zur Herstellung von basisch alkylierten Tetrahydrocarbazolen oder Indolen
US3151120A (en) * 1961-08-15 1964-09-29 Ciba Geigy Corp Thieno [3, 2-b] indole esters and amides
US3133930A (en) * 1961-08-15 1964-05-19 Ciba Geigy Corp Ester and amide derivatives of thieno-[3, 2-b] indole 3-carboxylic acids
US3329571A (en) 1961-10-24 1967-07-04 American Home Prod Methods for treating depression
NL284655A (es) 1961-10-24
US3142678A (en) * 1962-01-09 1964-07-28 American Home Prod Amino substituted penthienoindoles
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (es) * 1993-10-22 1996-02-11 Hoffmann La Roche
TW403738B (en) 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
WO1998030548A1 (en) 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. 5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES

Also Published As

Publication number Publication date
ES2228588T3 (es) 2005-04-16
AU773337B2 (en) 2004-05-20
WO2001012603A1 (en) 2001-02-22
BR0013307A (pt) 2002-05-28
ATE279392T1 (de) 2004-10-15
DE60014918T2 (de) 2005-10-13
CA2377646A1 (en) 2001-02-22
US6706750B1 (en) 2004-03-16
GB9918962D0 (en) 1999-10-13
AR037222A1 (es) 2004-11-03
KR100740172B1 (ko) 2007-07-16
EP1202965B1 (en) 2004-10-13
CN1368960A (zh) 2002-09-11
DE60014918D1 (de) 2004-11-18
ZA200110217B (en) 2002-12-12
CN1187330C (zh) 2005-02-02
MXPA01013235A (es) 2002-06-04
UY26291A1 (es) 2001-03-16
AU6455500A (en) 2001-03-13
KR20020015078A (ko) 2002-02-27
DK1202965T3 (da) 2005-02-14
PT1202965E (pt) 2005-01-31
TR200200352T2 (es) 2002-06-21
JP2003507367A (ja) 2003-02-25
EP1202965A1 (en) 2002-05-08

Similar Documents

Publication Publication Date Title
PE20010574A1 (es) Derivados de indol como ligandos del receptor 5-ht2
PE20010575A1 (es) Derivados de indol y su uso como ligandos del receptor 5ht2
PE20021094A1 (es) Derivados de ciclohexano-1,4-diamina sustituidos
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
PE20081316A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
PE20011030A1 (es) Combinaciones farmaceuticas que comprenden tegaserod y omeprazol
NO20052737L (no) N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them.
PE20010641A1 (es) Derivados de piperazina como antagonistas del receptor de serotonina 5-ht1b
AR041302A1 (es) Compuestos de imidazopiridina como agonistas del receptor 5- ht4 y composiciones farmaceuticas que comprenden dichos compuestos
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
ZA200600419B (en) Indol-6 sulfonamide derivatives, their preparation and their use as 5-HT-6 modulators
PE20030119A1 (es) Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6
PE20050465A1 (es) Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3
PE20010681A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
BRPI0607456A2 (pt) derivados de oxindol como agonistas do receptor 5ht4
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20081876A1 (es) Aminoamidas como antagonistas de orexina
Mattsson et al. 2-Alkyl-3-(1, 2, 3, 6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists
PE20021043A1 (es) DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2

Legal Events

Date Code Title Description
FC Refusal